Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 82 yuan [2][6]. Core Insights - The company's domestic business is experiencing temporary pressure, while overseas growth remains robust. In H1 2025, the company reported a revenue of 2.185 billion yuan, a decrease of 1.18% year-on-year, and a net profit attributable to shareholders of 771 million yuan, down 14.62% year-on-year [2][6]. - The overseas business saw a significant increase, with revenue reaching 952 million yuan in H1 2025, representing a year-on-year growth of 19.57% [6]. - The company is enhancing its high-end product matrix, with the flagship model MAGLUMIX10 achieving domestic product registration and a testing speed of 1,000 tests per hour, improving its competitive edge in the market [6]. Financial Performance Summary - **Revenue Forecasts**: - Total revenue is projected to grow from 4.535 billion yuan in 2024 to 6.633 billion yuan in 2027, with year-on-year growth rates of 15.4%, 7.4%, 15.9%, and 17.5% respectively [2][7]. - **Net Profit Forecasts**: - Net profit attributable to shareholders is expected to increase from 1.828 billion yuan in 2024 to 2.585 billion yuan in 2027, with growth rates of 10.6%, 1.5%, 16.5%, and 19.6% respectively [2][7]. - **Earnings Per Share (EPS)**: - EPS is forecasted to rise from 2.33 yuan in 2024 to 3.29 yuan in 2027 [2][7]. - **Valuation Ratios**: - The price-to-earnings (P/E) ratio is projected to decrease from 29 times in 2024 to 21 times in 2027, while the price-to-book (P/B) ratio is expected to decline from 6.3 times to 4.5 times over the same period [2][7]. Market Position and Strategy - The company has successfully expanded its customer base, with 1,835 tertiary hospitals served by the end of H1 2025, achieving a coverage rate of 47.60% [6]. - The sales of high-end models in overseas markets have increased, with 1,971 units of the chemical luminescence immunoassay analyzer sold in H1 2025, and the proportion of mid-to-high-end models reaching 77.02% [6].

Core Insights - The article highlights the transformation of 桃江 from a traditional bamboo-producing region to a manufacturing hub, driven by new industrial projects and investments from businesses [1][2]. Group 1: Company Developments - Hunan Fude Electric Co., Ltd. has received orders from a computing power center that are scheduled until next year, indicating strong demand for its products [1]. - The company has established a postdoctoral research workstation, the first of its kind in 桃江, to foster talent development in the region [1]. - Hunan Yixin Technology Co., Ltd. has relocated its focus from Shenzhen to 桃江, establishing a new optical film coating production base that achieved large-scale production in August 2023 [2]. Group 2: Industry Growth - 桃江's industrial landscape is diversifying with new projects in electric motor components, smart home manufacturing, and hospitality, enhancing the region's industrial structure [2]. - The bamboo industry in 桃江 is expanding into various sectors, including carbon-based materials, new building materials, consumer goods, and bio-extraction, with plans for a full industry chain extension [2]. - The introduction of a green low-carbon bamboo intelligent recycling industrial park aims to utilize bamboo resources for producing high-value products while promoting sustainability [2].

Group 1 - The core point of the news is that New Industry has seen significant trading activity, with a total of 2 block trades on September 30, amounting to 360,000 shares and a total transaction value of 24.588 million yuan, with a consistent trading price of 68.30 yuan [2][3] - The stock closed at 68.30 yuan, reflecting an increase of 1.83% for the day, with a turnover rate of 0.42% and a total trading volume of 197 million yuan, indicating a net inflow of 16.7997 million yuan from main funds [2][3] - Over the past five days, the stock has increased by 2.91%, with a cumulative net inflow of 33.8591 million yuan [2] Group 2 - The latest margin financing balance for the stock is 802 million yuan, which has increased by 16.7826 million yuan over the past five days, representing a growth rate of 2.14% [3] - New Industry Biomedical Engineering Co., Ltd. was established on December 15, 1995, with a registered capital of 785.718785 million yuan [3] - The block trades on September 30 included two transactions, with 200,000 shares traded for 13.66 million yuan and 160,000 shares for 10.928 million yuan, both at a price of 68.30 yuan, with no premium or discount relative to the closing price [3]

Core Viewpoint - Sequoia Capital has announced a plan to reduce its stake in New Industry (300832.SZ) after holding shares for 14 years, indicating a potential shift in investment strategy [1] Group 1: Shareholder Reductions - Sequoia Capital plans to reduce its holdings by up to 14,500,000 shares, which is approximately 1.8454% of the total share capital, through block trading within three months after the announcement [1] - Director Ms. Rao Jie intends to sell up to 1,500,000 shares, representing about 0.1909% of the total share capital, also within three months after the announcement [2] - Senior management member Ms. Liu Haiyan plans to reduce her holdings by up to 100,000 shares, which is around 0.0127% of the total share capital, within the same timeframe [2]

Core Viewpoint - Sequoia Capital, holding 10.6214% of the shares, plans to reduce its stake by up to 14.5 million shares, representing 1.8454% of the total share capital, within three months after the announcement of the reduction plan [1] Group 1 - Shareholder Sequoia Capital intends to sell up to 14.5 million shares through block trading [1] - Director Rao Jie plans to reduce his holdings by up to 150,000 shares, accounting for 0.1909% of the total shares [1] - Senior management member Liu Haiyan aims to sell up to 100,000 shares via centralized bidding, which represents 0.0127% of the total shares [1]

特别提示： 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 公司持股 5%以上的股东天津红杉聚业股权投资合伙企业（有限合伙）（以下简 称"红杉聚业"或"天津红杉"）出具的《关于新产业减持计划的告知函》，以 及公司董事饶捷女士、公司高级管理人员刘海燕女士分别出具的《关于股份减持 计划的告知函》。 1、 红杉聚业于 2011 年完成对公司的投资，是公司自设立以来首轮融资中唯 一的创投机构，投资期长达 14 年。红杉聚业持有本公司股份 83,454,063 股（占 本公司总股本的 10.6214%），该部分股份已于 2023 年 5 月 12 日解除限售并上市 流通。红杉聚业计划自本减持计划公告之日起 15 个交易日后的 3 个月内通过大 宗交易方式减持本公司股份的数量不超过 14,500,000 股（按公司截至告知函出具 日的股份总数 785,718,785 股计算，对应的股份比例为不超过公司总股本的 1.8454%）。若在本减持计划公告日至减持时间区间届满日期间公司有送股、资 本公积金转增股本、配股等股份变动事项，减持股份数量进行相应调整。 2、 公司董事饶捷女士持有公司股份 24,466, ...

Group 1 - The company Shenzhen New Industry Biomedical Engineering Co., Ltd. has conducted a series of investor relations activities from September 1 to September 28, 2025 [1] - The activities included on-site visits, online communications, and strategy meetings with major financial institutions such as UBS and HSBC, involving a total of 38 institutions and 75 participants [1] - The company maintained a stable information disclosure rhythm, with no new major interactive content reported during this event, indicating consistent communication with investors [1]

Group 1: Event Overview - The investor relations activities took place from September 1 to September 28, 2025 [2] - The location of the activities was at the New Industry Biomedical Building, No. 23, Jinxiu East Road, Kengzi Street, Pingshan District, Shenzhen [2] - A total of 38 institutions participated, with 75 attendees [2] Group 2: Participants and Activities - The activities included on-site visits and various online strategy meetings with institutions such as UBS and HSBC [2] - Key personnel from the company included Chairman and General Manager Rao Wei, Deputy General Manager and Board Secretary Zhang Lei, and Investor Relations Head Lü Yuning [2] - No new major communication content was introduced beyond previously disclosed investor relations activities [2] Group 3: Attending Institutions - Notable participating institutions included AllianceBernstein, DawnLight Capital, and Polar Capital [3] - Other participants included various fund management companies such as Southern Fund Management and Ping An Pension Insurance [3][4]

Group 1 - On September 30, a total of 360,000 shares of New Industry were traded in block transactions, with a transaction value of 24.588 million yuan, accounting for 11.12% of the total transaction value for the day [1] - The transaction price was 68.3 yuan, which remained stable compared to the market closing price of 68.3 yuan [1] - The block transactions included two separate trades, one for 200,000 shares valued at 13.66 million yuan and another for 160,000 shares valued at 10.928 million yuan, both executed by institutional investors [2]

Core Insights - The conference focused on three main areas: "Good Housing," "Urban Renewal," and "Science and Technology Innovation Industry" [1] - Over a hundred innovative construction technology products were showcased at the event [1] - Discussions included topics such as intelligent construction, intelligent design, and industry-academia-research collaboration [1] Company Highlights - China State Construction Engineering Corporation's Eighth Engineering Bureau released solutions for urban renewal, intelligent construction, and green low-carbon technology innovations [1] Industry Developments - The event featured an exhibition showcasing innovations in construction industrialization, intelligent construction, green low-carbon technologies, digital industries, and new building materials [1]